Quilter Plc increased its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 12.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 280,032 shares of the company’s stock after acquiring an additional 31,299 shares during the quarter. Zoetis comprises about 1.1% of Quilter Plc’s holdings, making the stock its 28th biggest holding. Quilter Plc owned 0.06% of Zoetis worth $48,546,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Focus Financial Network Inc. ADV purchased a new position in shares of Zoetis during the 4th quarter valued at $2,159,000. Price T Rowe Associates Inc. MD boosted its stake in Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after buying an additional 3,244,074 shares during the period. Axiom Investors LLC DE grew its position in Zoetis by 36.3% during the fourth quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock worth $117,331,000 after buying an additional 158,459 shares in the last quarter. Global Assets Advisory LLC purchased a new stake in shares of Zoetis in the 1st quarter valued at about $8,831,000. Finally, Franklin Street Advisors Inc. NC boosted its position in shares of Zoetis by 4.3% during the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock valued at $20,478,000 after acquiring an additional 5,035 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Stock Performance
Zoetis stock opened at $191.09 on Friday. The firm has a fifty day simple moving average of $182.85 and a two-hundred day simple moving average of $174.32. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market capitalization of $86.57 billion, a PE ratio of 36.82, a P/E/G ratio of 2.92 and a beta of 0.88.
Wall Street Analyst Weigh In
ZTS has been the topic of a number of recent analyst reports. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus price target of $217.11.
Read Our Latest Stock Analysis on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
- Five stocks we like better than Zoetis
- Using the MarketBeat Dividend Tax Calculator
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is the Euro STOXX 50 Index?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- How to Invest in the FAANG Stocks
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.